Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00470834 · ClinicalTrials.gov registry record · Phase 4

Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy

A Phase 4 study of Neoplasms Prostate, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 4
Development phase
127
Enrollment target
20
Study locations

NCT00470834 is a Phase 4 study of Neoplasms Prostate that has completed, run by GlaxoSmithKline. The registered enrollment target is 127 participants, below the 3,087-participant average among 6 other Neoplasms Prostate trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00470834, a Phase 4 study of Neoplasms Prostate, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 4
Development phase
127 participants
Enrollment target
20
Study locations

Study Summary

Dutasteride inhibits the conversion of testosterone to dihydrotestosterone (DHT) the male hormone that leads to benign prostate growth. By blocking the conversion of testosterone to DHT, dutasteride could allow bicalutamide to be a more effective anti-androgen thus prolonging bicalutamide's efficacy.

Conditions Studied

Neoplasms Prostate

Interventions

  • DRUG placebo
  • DRUG bicalutamide
  • DRUG dutasteride

Study Locations (20)

California

  • GSK Investigational Site - Anaheim
  • GSK Investigational Site - Fresno
  • GSK Investigational Site - San Bernardino
  • GSK Investigational Site - San Diego

Florida

  • GSK Investigational Site - Aventura
  • GSK Investigational Site - Daytona Beach
  • GSK Investigational Site - Orlando

Indiana

  • GSK Investigational Site - Evansville
  • GSK Investigational Site - Fort Wayne
  • GSK Investigational Site - Jeffersonville

Alabama

  • GSK Investigational Site - Homewood
  • GSK Investigational Site - Huntsville

Louisiana

  • GSK Investigational Site - New Orleans
  • GSK Investigational Site - Shreveport

Arkansas

  • GSK Investigational Site - Little Rock

Colorado

  • GSK Investigational Site - Denver

District of Columbia

  • GSK Investigational Site - Washington D.C.

Trial Details

FieldValue
Enrollment Target 127 participants
Start Date 2007-05
Est. Completion 2013-02
Phase Phase 4

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00470834

The ClinicalTrials.gov registry entry for NCT00470834 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,087-participant average among 6 other Neoplasms Prostate trials with a reported enrollment target (96% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neoplasms Prostate appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.

NCT00470834 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Indiana.

Frequently Asked Questions

What is clinical trial NCT00470834 about?

NCT00470834 is a clinical study titled "Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy". Dutasteride inhibits the conversion of testosterone to dihydrotestosterone (DHT) the male hormone that leads to benign prostate growth. By blocking the conversion of testosterone to DHT, dutasteride could allow bicalutamide to be a more effective anti-androgen thus prolonging bicalutamide's efficacy...

What is the current status of trial NCT00470834?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 127 participants. The study started on 2007-05. Estimated completion is 2013-02.

What conditions does trial NCT00470834 study?

This clinical trial studies the following conditions: Neoplasms Prostate.

What interventions are being tested in trial NCT00470834?

The interventions under investigation include: placebo (DRUG), bicalutamide (DRUG), dutasteride (DRUG).

Who is sponsoring clinical trial NCT00470834?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00470834 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neoplasms Prostate

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neoplasms Prostate

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.